The Burden of ASCVD and Evidence-Based Guidelines

Ian Riddock, MD, discusses the burden of atherosclerotic cardiovascular disease (ASCVD) and multi-societal guideline recommendations for lipid management.

Now Viewing

EP: 1.The Burden of ASCVD and Evidence-Based Guidelines

EP: 2.A Patient’s Post-MI Journey

EP: 3.Improving the Care Continuum

EP: 4.Residual Cardiovascular Risk

EP: 5.Who is an Ideal Patient for Early Intensive Lipid Lowering?

EP: 6.Finding the Optimal Statin Dose

EP: 7.Therapy Beyond Statins in the Inpatient Setting

EP: 8.Using Adjunct Therapies in LDL Management

EP: 9.Ensuring Continuity of Care for the ASCVD Patient

EP: 10.Unmet Needs in Lipid Management

EP: 11.Defining “Optimal Care” for ASCVD Within Health Systems

EP: 12.What Does a Multidisciplinary Team Look Like?

EP: 13.The Future of LDL Management for Patients With High-Risk ASCVD

EP: 14.Enhancing Patient Care Through Guideline Adherence

EP: 15.Improving Access to PCSK9 Inhibitors in the Inpatient Setting

EP: 16.Appropriate ASCVD Treatment Outside of Closed Health Systems

EP: 17.Utilizing Quality Metrics in ASCVD

EP: 18.Improving Patient and Provider Engagement

EP: 19.Treatment Disparities in the Management of ASCVD

Related Videos

Related Content

Advertisement

July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Hayden E. Klein

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 15th 2025

Potential Link Found Between Obesity and Myasthenia Gravis Exacerbation

Maggie L. Shaw

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 14th 2025

Colorectal Cancer Shared Care Model Gains Support From Clinicians

Pearl Steinzor

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).

Related Content

Advertisement

July 17th 2025

Direct-to-Patient Apixaban Program Aims to Expand Access, Lower Out-of-Pocket Costs

Hayden E. Klein

Apixaban would still cost patients 9 times more through the Eliquis 360 Support program than with commercial insurance.

December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.

July 15th 2025

Potential Link Found Between Obesity and Myasthenia Gravis Exacerbation

Maggie L. Shaw

Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of Daily Living response, and Minimal Symptom Expression.

December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.

July 14th 2025

Colorectal Cancer Shared Care Model Gains Support From Clinicians

Pearl Steinzor

New insights highlight clinician support for shared survivorship care and identify key factors for effective implementation.

July 14th 2025

HALP Score Acts as Prognostic Biomarker for Survival Outcomes in NSCLC

Julia Bonavitacola

The hemoglobin, albumin, lymphocyte, and platelet (HALP) score can help to guide treatment decisions in patients living with non–small cell lung cancer (NSCLC).